In a turbulent market environment, SLXN, also known as Moringa Acquisition Corp, saw its share price fall to a 52-week low, hitting a worrying $1.82. With a market cap of just $2.99 million and a weak financial health rating according to InvestingProthe company faces significant challenges. This significant decline reflects an incredible 1-year change, with the company’s stock value falling -98.04%. Investors are watching SLXN closely as it navigates these challenging financial waters, with hopes for a strategic turnaround that could potentially rejuvenate the stock’s performance in the coming months. InvestingPro analysis reveals high price volatility, with 7 additional key insights available to subscribers.
In other recent news, Silexion Therapeutics Corp announced a 1-for-9 reverse split of its common stock, a strategic move approved by shareholders. This development consolidates the issued and valid ordinary shares of the company, increasing the nominal value of each share. In addition, Silexion made adjustments to its outstanding warrants, reducing the number of common shares issuable upon exercise of the warrants and increasing the exercise price to $103.50 per share.
In the clinical development arena, Silexion has made significant progress in its preclinical studies for SIL-204, an siRNA candidate targeting KRAS-driven cancers. It is preparing to move into Phase 2/3 clinical trials in the first half of 2026. The company also reported improved results from its Phase 2 trial of LODER™ in the treatment of locally advanced pancreatic cancer.
Finally, Silexion announced the immediate resignation of board member Ilan Shiloah due to time constraints. This leaves vacancies on the audit, compensation, corporate governance and nominating committees. These are the latest achievements in the course of the corporate evolution of Silexion Therapeutics Corp.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
